Atlantic Union Bankshares Corp Has $2.23 Million Stake in Danaher Co. (NYSE:DHR)

Atlantic Union Bankshares Corp lowered its holdings in Danaher Co. (NYSE:DHR) by 0.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,929 shares of the conglomerate’s stock after selling 58 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Danaher were worth $2,230,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP raised its holdings in shares of Danaher by 12.0% in the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after acquiring an additional 2,998,161 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares during the last quarter. Capital International Investors lifted its holdings in shares of Danaher by 9.1% in the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after purchasing an additional 1,334,781 shares in the last quarter. Norges Bank purchased a new position in shares of Danaher during the fourth quarter valued at approximately $1,752,382,000. Finally, Franklin Resources Inc. grew its holdings in Danaher by 6.4% during the fourth quarter. Franklin Resources Inc. now owns 6,620,170 shares of the conglomerate’s stock worth $1,531,510,000 after buying an additional 395,498 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other news, Director Alan G. Spoon sold 708 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now directly owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now directly owns 116,202 shares in the company, valued at $28,304,483.16. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The disclosure for this sale can be found here. Insiders sold a total of 148,783 shares of company stock worth $37,536,717 in the last quarter. 11.10% of the stock is owned by company insiders.

Danaher Price Performance

Shares of NYSE:DHR opened at $250.03 on Friday. The company has a 50-day moving average price of $255.96 and a two-hundred day moving average price of $246.43. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $269.11. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $185.19 billion, a PE ratio of 42.38, a P/E/G ratio of 3.85 and a beta of 0.85.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same period last year, the firm earned $2.36 EPS. Danaher’s revenue for the quarter was down 2.6% on a year-over-year basis. Equities analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of analyst reports. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday. Jefferies Financial Group initiated coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price on the stock. Robert W. Baird upped their target price on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Citigroup lifted their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, TD Cowen upped their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.